- Treat, the Helsinki-based AI healthtech company, has raised €3 million in pre-seed funding.
- The funding round was led by byFounders and Illusian, founded by Ilkka Paananen of Supercell.
- Sami Marttinen, former CEO of Swappie, says the deal was done in one week.
Treat, the AI-focused healthtech company based in Helsinki, has raised €3 million in pre-seed funding led by byFounders and Illusian, founded by Ilkka Paananen of Supercell.
The Finnish startup was founded in 2026 by Sami Marttinen, co-founder and former CEO of Swappie, medical doctor Antti Mauno and fintech engineering lead Onni Wahlberg. The platform connects patients to doctors in minutes once the doctors have had a chance to review the patient’s medical history.
How a single A4 page led to the creation of Treat
Marttinen told Tech Funding News the idea came about three and a half years ago when his wife was going through nine separate private doctor visits before finally getting a diagnosis. Even with Finland’s national medical records system, which allows doctors to access both private and public records, he said, “Nobody had time to go through her records. So she was back at square one every single time.”
After the 7th visit, he was “personally fed up.” He went through all the visits, all the meds and all the tests and boiled it down to a single A4 page. The 8th doctor read that summary and referred her on to the specialist who made the diagnosis.
“Three years ago, my wife had to go through nine repeat doctor visits in private care before receiving a diagnosis. All the necessary information existed, but nobody had the incentive to connect the dots,” said Marttinen.
He elaborated further: “The problem isn’t the doctors. It’s an economic model that rewards repeat visits over efficient resolution. Treat makes zero revenue from lab tests, clinic visits, or referrals. Our only incentive is solving the patient’s issue on the spot.”
After interviewing doctors, patients and medtech founders, Marttinen concluded: “There’s an incentive problem, and there’s a technology problem, and you need to fix both to fix this.”
How Treat works and who uses the service
Patients can type or verbally state their symptoms, and the AI then poses a series of follow-up questions to gather the information the doctor needs. Treat’s system also checks their insurance and employer coverage so they don’t have to choose between a nurse, a doctor, or a specialist.
The company stresses that no patient records or other identifiable data are shared with public LLMs and that only a licensed doctor can access a patient’s medical history and make clinical decisions.
Marttinen says Treat has no direct competitors. The only indirect competition would be from occupational healthcare and insurance providers, which he describes as indirect competitors. He refers to Treat as an operating layer that sits on top of those contracts. According to company claims, 83% of cases are resolved on the first visit.
Treat developed the product over the spring and summer, with test users being on board in August whilst still in stealth. They now have over 20 pilot employers, mostly global businesses, including a 1,300-employee company, and are at the point where they have their first thousands of users. Finnish users can access the service across Europe, add travel insurance and use prescriptions in other countries.
“Private healthcare across the globe is bogged down by fragmented systems and mismatched incentives. Treat fixes this at the root. By stripping away billable runarounds and aligning technology directly with clinical workflows, the team behind Treat is building a new benchmark for primary care,” said Sara Rywe, general partner at byFounders.
A one-week funding round and a goal to reach five countries
Marttinen set out the problem and went looking for the right mix of co-founders with both a tech and a medical background. He stepped down from his roles as Swappie advisor and board member last year, then worked with the co-founders before fully committing. The founding team now has nine members.
He described the fundraising process as “surprisingly smooth” and confirmed that byFounders was Treat’s preferred investor. The round closed just one week after the first conversation. The €3 million will mainly go toward product development and expansion.
Treat is joining a very competitive Nordic AI health sector. Gosta Labs in Helsinki raised a €7.5 million seed for oncology. Oura has agreed to buy AI-native primary care company Counsel Health for $625 million. Tandem Health have also raised $100 million from Scaleup Europe Fund to develop an AI clinic OS for Europe.
Marttinen expects Treat to be active in over five countries by the end of the year and is confident that tens of millions of people will have access in the coming years. The employer pilot programme will tell us whether the no-referral model will work at that scale.